Yasmin Karimi

Lymphoma MD at University of Michigan, intent on ensuring optimal health care delivery and hiking every national park in the US.

All opinions my own.

[Yasmin Karimi @Yhkarimi]

@MediHumdani @DunleavyKieron @TheIACH There is accumulating retrospective data that RCHOP and even abbreviated therapy (less than 6 cycles) may be adequate for patients with early stage DHL/THL.

Do you treat all patients with HGBCL with DA-EPOCH-R, or only those with advanced stage disease?

[Yasmin Karimi @Yhkarimi]

What is your choice of salvage chemotherapy in a 28 yo patient with primary refractory classical Hodgkins lymphoma after 6 cycles of ABVD?

We go through the current data and our approach in a recent review: https://t.co/v2mwMpYO8M

[Adam Cifu @adamcifu]

It's also the time of year when people become "new attendings." Some advice.

[Toby Eyre @tobyeyre82]

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts https://t.co/0c5SEk6v4B

[Yasmin Karimi @Yhkarimi]

Updated analysis of ECHELON-1 at #ASCO22 showed OS benefit to BV-AVD arm compared to ABVD in untreated advanced stage cHL!

- Median fu 73 mo
- 6 yr OS 93.9% vs. 89.%
- HR for OS 0.59 (95%CI 0.396-0.879; p=0.009)
- Fewer secondary malignancies w BV-AVD

[Toby Eyre @tobyeyre82]

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab https://t.co/Frds9R3bE6

[Yasmin Karimi @Yhkarimi]

@MediHumdani Data from Tandem 2022 on alloSCT post Cd19 CART in RR DLBCL (Zurko et al):

1 yr OS/PFS: 51%, 40%
1 yr non relapse mortality 27%
10% G3/4 acute GVHD
28% chronic GVHD at 1 yr

Allo is very toxic but reasonable--need longer follow up! Alternatively, consider bispecifics or trials.

[Yasmin Karimi @Yhkarimi]

@AaronGoodman33 @matthew_mei @graham74GC I have started to lean more towards sequential BV-AVD-BV (particularly in stage IV, high IPS score) as it is a challenge to know how best to tx after 2 ABVD per RATHL if PET2 positive...Can't escalate to beacopp, shouldn't continue bleo.

[Yasmin Karimi @Yhkarimi]

@AaronGoodman33 I would avoid ICE since relapse so quickly after 1st line tx. Would use Pembro-GVD: all output, high response rates.

Data that CPIs resenitize tumor to cytotoxic chemo and benefit to autoSCT.
:https://t.co/Ba6iQDQ1sw

Question is whether you do BV maint post auto per ATHERA??

[Yasmin Karimi @Yhkarimi]

@BijoyTelivala @Berninini @AaronGoodman33 @emouMD Agree- approach to 2nd line Auto vs. CART will depend on:

- Duration of CR1
- Disease burden (need to use salvage chemo vs bridging steroids)
- How quickly can be referred to cellular therapies program, obtain insurance auth and undergo apheresis
- Co morbidites precluding auto

[Yasmin Karimi @Yhkarimi]

CART now approved in the 2nd line setting for DLBCL, for pts with relapse <12 mo after 1st line tx or primary refractory disease based on Zuma 7 data.

@AaronGoodman33, @Berninini, @emouMD How would you now treat a 60 yo patient with DLBCL relapsed 9 mo after RCHOP?

[Yasmin Karimi @Yhkarimi]

@emouMD @AaronGoodman33 @Berninini Agreed! There is still a role for autoSCT in 2nd line setting. In Zuma-7, similar duration of response in Axi-cel vs. SOC arms in responding patients.

[Bernie Marini @Berninini]

So #twitterx doesn't throw me in Twitter jail, here are 10 #ASH21 abstracts...as HARRY POTTER characters.

I couldn't decide if I should rank based on "impactful" or "practice changing", so these are some that I think everyone should *read carefully*, and I tried to make it fun!

[Yasmin Karimi @Yhkarimi]

On round today, seeing a patient with altered mental status:

Me: Who is the president of the US?

Team behind me: *cumulative sigh of relief*

...Four years later, it's a nice feeling to not cringe during neuro exams again.

[Yasmin Karimi @Yhkarimi]

Grateful to have received the CancerLinQ Discovery Award from @ASCO. Excited about the work and feel so fortunate to be part of a great QI team at Stanford!

[DrDoug @BlayneyDouglas]

The hits just keep on coming for Dr. Karimi! Congrats.

[Yasmin Karimi @Yhkarimi]

The more you look, the more gender bias you find! https://t.co/ThuF3qZ3DY @cathryntlee @MedChiefs #WIM